Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew S Lee

Showing results (61-70 of 66) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 66 results.
Urology|January 15, 2026
Response to Editorial Comment on "Clinical Outcomes Comparing Mini Versus Standard PCNL without Postoperative Nephrostomy Tube: A Multi-Institutional Randomized Controlled Trial from the EDGE Consortium"Tyler Sheetz, Jamie L Finegan, Sri Sivalingam, et al.
Journal of Medicinal Chemistry|February 12, 2013
Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR)Craig S Takeuchi, Byung Gyu Kim, Charles M Blazey, et al.
Open Forum Infectious Diseases|October 7, 2024
Implementing the Infectious Diseases Society of America Antimicrobial Stewardship Core Curriculum: Survey Results and Real-World Strategies to Guide Fellowship ProgramsLeila S Hojat, Payal K Patel, Dilek Ince, et al.
Journal of Medicinal Chemistry|May 3, 2012
Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-kinase γ inhibitorsJames W Leahy, Chris A Buhr, Henry W B Johnson, et al.
Bioorganic & Medicinal Chemistry Letters|November 7, 2012
SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitorsTimothy Forsyth, Patrick C Kearney, Byung Gyu Kim, et al.
Cell|May 21, 2021
Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodiesWilton B Williams, R Ryan Meyerhoff, R J Edwards, et al.
Pageof 7

Showing results (61-70 of 66) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 66 results.
Urology|January 15, 2026
Response to Editorial Comment on "Clinical Outcomes Comparing Mini Versus Standard PCNL without Postoperative Nephrostomy Tube: A Multi-Institutional Randomized Controlled Trial from the EDGE Consortium"Tyler Sheetz, Jamie L Finegan, Sri Sivalingam, et al.
Journal of Medicinal Chemistry|February 12, 2013
Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR)Craig S Takeuchi, Byung Gyu Kim, Charles M Blazey, et al.
Open Forum Infectious Diseases|October 7, 2024
Implementing the Infectious Diseases Society of America Antimicrobial Stewardship Core Curriculum: Survey Results and Real-World Strategies to Guide Fellowship ProgramsLeila S Hojat, Payal K Patel, Dilek Ince, et al.
Journal of Medicinal Chemistry|May 3, 2012
Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-kinase γ inhibitorsJames W Leahy, Chris A Buhr, Henry W B Johnson, et al.
Bioorganic & Medicinal Chemistry Letters|November 7, 2012
SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitorsTimothy Forsyth, Patrick C Kearney, Byung Gyu Kim, et al.
Cell|May 21, 2021
Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodiesWilton B Williams, R Ryan Meyerhoff, R J Edwards, et al.
Pageof 7